FindTrial
Sign In

Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05466578
Enrollment
Unknown
Registered
2022-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Uncontrolled Atopic Dermatitis

Keywords

atopic dermatitis, AD, Atopic eczema, JAK inhibitors

Brief summary

Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis

Detailed description

In Expanded Access, treating physicians are the Sponsor. Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ; availability will depend on location/country.

Interventions

DRUGabrocitinib

Sponsors

Pfizer
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum

Inclusion criteria

Must have severe uncontrolled atopic dermatitis refractory to other available treatments

Contacts

Primary ContactPfizer Cares
pfizercares@pfizer.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026